Shanghai S.E.
06:00:00 2024-04-25 pm EDT
5-day change
1st Jan Change
29.48
CNY
-0.37%
+2.97%
-22.58%
Chengdu WestGene Biomedical Technology Co., Ltd. announced that it has received $63.25 million in funding from Qingdao Honline Huaxin Asset Management Co., Ltd., Beijing Konruns Pharmaceutical Co.,Ltd., Hangzhou Tigermed Consulting Co., Ltd, Chengdu Guanghua Wutong Equity Investment Fund Management Co., Ltd., Yingke Innovation Asset Management Co., Ltd.
On June 20, 2023, Chengdu WestGene Biomedical Technology Co., Ltd. closed the transaction. The company has amended the terms of the transaction. The company has received $41.8 million in its second and final tranche.
The company has received funding $63.25 million funding till date. The transaction included participation from new investor Beijing Konruns Pharmaceutical Co.,Ltd. and returning investor Hangzhou Tigermed Consulting Co., Ltd.
Beijing Konruns Pharmaceutical Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024
Apr. 25
CI
Beijing Konruns Pharmaceutical Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023
Apr. 08
CI
Konruns Pharma Enrolls First Subject in Phase 3 Study of Cancer Drug
Feb. 06
MT
Beijing Konruns Pharmaceutical Gets Nod to Test KC1036 Tablets as Esophagus Cancer Treatment
Dec. 27
MT
Konruns Pharmaceutical Gets Clearance for Clinical Trial of Sarcoma Treatment
Dec. 20
MT
Beijing Konruns Pharmaceutical Co.,Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023
23-10-27
CI
Certain A Shares of Beijing Konruns Pharmaceutical Co.,Ltd. are subject to a Lock-Up Agreement Ending on 27-AUG-2023.
23-08-26
CI
Beijing Konruns Pharmaceutical Co.,Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023
23-07-31
CI
Chengdu WestGene Biomedical Technology Co., Ltd. announced that it has received $63.25 million in funding from Qingdao Honline Huaxin Asset Management Co., Ltd., Beijing Konruns Pharmaceutical Co.,Ltd., Hangzhou Tigermed Consulting Co., Ltd, Chengdu Guanghua Wutong Equity Investment Fund Management Co., Ltd., Yingke Innovation Asset Management Co., Ltd.
23-06-19
CI
Beijing Konruns Pharmaceutical Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023
23-04-25
CI
Chengdu WestGene Biomedical Technology Co., Ltd. announced that it has received $21.45 million in funding from Qingdao Honline Huaxin Asset Management Co., Ltd.,Yingke Innovation Asset Management Co., Ltd.,Chengdu Guanghua Wutong Equity Investment Fund Management Co., Ltd. and Hangzhou Tigermed Consulting Co., Ltd.
22-12-05
CI
Beijing Konruns Pharmaceutical Co.,Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022
22-10-25
CI
Certain A Shares of Beijing Konruns Pharmaceutical Co.,Ltd. are subject to a Lock-Up Agreement Ending on 27-AUG-2022.
22-08-26
CI
Beijing Konruns Pharmaceutical Co.,Ltd. cancelled the transaction announced on March 1, 2021
22-07-14
CI
Beijing Konruns Pharmaceutical Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022
22-04-22
CI
Tranche Update on Beijing Konruns Pharmaceutical Co.,Ltd.'s Equity Buyback Plan announced on January 21, 2021.
22-01-19
CI
Beijing Konruns Pharmaceutical Co.,Ltd.'s Equity Buyback announced on January 21, 2021, has expired with 2,273,523 shares, representing 1.44% for CNY 79.31 million.
22-01-18
CI
Tranche Update on Beijing Konruns Pharmaceutical Co.,Ltd.'s Equity Buyback Plan announced on January 21, 2021.
22-01-04
CI
Beijing Konruns Pharmaceutical Co.,Ltd. completed the acquisition of 13.70% stake in Beijing Konruns Biotechnology Co., Ltd. from NT Pharma Pacific Company Limited.
21-11-03
CI
Beijing Konruns Pharmaceutical Co.,Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2021
21-10-25
CI
Beijing Konruns Pharmaceutical Co.,Ltd. intends to acquire 13.70% stake in Beijing Konruns Biotechnology Co., Ltd. from NT Pharma Pacific Company Limited for approximately CNY 130 million.
21-10-11
CI
Certain A Shares of Beijing Konruns Pharmaceutical Co.,Ltd. are subject to a Lock-Up Agreement Ending on 27-AUG-2021.
21-08-26
CI
Beijing Konruns Pharmaceutical Co.,Ltd. Reports Earnings Results for the Half Year Ended June 30, 2021
21-08-23
CI
Tranche Update on Beijing Konruns Pharmaceutical Co.,Ltd.'s Equity Buyback Plan announced on January 21, 2021.
21-07-01
CI
Beijing Konruns Pharmaceutical Co.,Ltd.(XSSC:603590) dropped from S&P Global BMI Index
21-06-21
CI
Duration Auto. 2 months 3 months 6 months 9 months 1 year 2 years 5 years 10 years Max.
Period Day Week
More charts
Beijing Konruns Pharmaceutical Co., Ltd. is a China-based company principally engaged in the research and development, production and sales of drugs. The Company's main product Suling belongs to the haemocoagulase drug that activates the coagulation process, which is mainly used for hemostasis of superficial wound bleeding in surgical operations as well as the bleeding caused by postoperative, trauma and disease. The Companyâs present products under research include a range of innovative and generic drugs for tumors and blood. The Company mainly distributes its products in the domestic market.
More about the company
Last Close Price
29.48
CNY
Average target price
44
CNY
Spread / Average Target
+49.25%
Consensus
1st Jan change
Capi.
-22.58% 637M +25.83% 661B +27.00% 566B -6.76% 352B +20.34% 332B +3.00% 283B +13.09% 231B +5.46% 200B -9.61% 195B -6.26% 145B
Other Pharmaceuticals
Stock Market Equities 603590 Stock
News Beijing Konruns Pharmaceutical Co.,Ltd. Chengdu WestGene Biomedical Technology Co., Ltd. announced that it has received $63.25 million in funding from Qingdao Honline Huaxin Asset Management Co., Ltd., Beijing Konruns Pharmaceutical Co.,Ltd., Hangzhou Tigermed Consulting Co., Ltd, Chengdu Guanghua Wutong Equity Investment Fund Management Co., Ltd., Yingke Innovation Asset Management Co., Ltd.
+951% of historical
More than 20 years
Our Experts
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1
BEIJING KONRUNS PHARMACEUTICAL CO.,LTD. 
